Fresenius Kabi clinical trials

Part of Fresenius SE & Co. KGaA, which holds 100% as of 2025-12-31. Source

The registry lists 90 studies whose lead sponsor is Fresenius Kabi or one of 9 companies grouped under it. 8 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 90. Browse all 90 →

• Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult PatientsRecruitingNCT06049680Phase 4
• Suitability of a High-energy, Low-protein Formula (Renalive® LP)RecruitingNCT06892249Not applicable

  Sponsor listed in the registry: Fresenius Kabi Taiwan Ltd.

• Evaluation of Safety and Efficacy of Supportan® DrinkRecruitingNCT06902402Not applicable

  Sponsor listed in the registry: Fresenius Kabi Taiwan Ltd.

• Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven TreatmentRecruitingNCT06274788
• Glycaemic Index Measurement of an Oral Nutritional Supplement With Biomarker Assessment and Lifestyle Monitoring in Healthy ParticipantsNot yet recruitingNCT07479251Not applicable
• Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] MelanomaRecruitingNCT07221734Phase 3

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted after mAbxience Research S.L. became part of Fresenius Kabi

• To Test the Food for Special Medical Purpose in Perioperative Patients With Gastrointestinal CancerRecruitingNCT05606848Not applicable

  Sponsor listed in the registry: Fresenius Kabi Sino-Swed Pharmaceutical Corp. Ltd · Fresenius Kabi Sino-Swed Pharmaceutical Corp. Ltd — acquired company within the Fresenius Kabi group

• SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory DiseasesRecruitingNCT05598684

  Sponsor listed in the registry: Fresenius Kabi, France

• A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid ArthritisCompletedNCT06596772Phase 3

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted after mAbxience Research S.L. became part of Fresenius Kabi

• A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)Active, not recruitingNCT06687369Phase 3

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted after mAbxience Research S.L. became part of Fresenius Kabi

• Evaluation of the Aurora Xi New Nomogram Software 2.0CompletedNCT06122935Not applicable

  Sponsor listed in the registry: Fenwal, Inc. · First submitted after Fenwal, Inc. became part of Fresenius Kabi

• A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune DisordersCompletedNCT06392074Phase 1

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted after mAbxience Research S.L. became part of Fresenius Kabi

• Real World Use of Tocilizumab Biosimilar studYActive, not recruitingNCT06247722

  Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · First submitted after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi

• A PK Study Comparing MB05, EU-sourced Synagis® and US-sourced Synagis® in Healthy Volunteers.CompletedNCT05121246Phase 1

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi

• A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.CompletedNCT05338086Phase 3

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi

• A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With OsteoporosisCompletedNCT04934072Phase 3

  Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · First submitted after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi

• A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced XgevaCompletedNCT05299073Phase 1

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi

• A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®.CompletedNCT04408989Phase 1

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi

• Chronic Kidney Disease Observational Database - TaiwanCompletedNCT03619564
• Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive CareCompletedNCT05257031Phase 3
• Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal SurgeryCompletedNCT03278548Phase 4
• MSB11022 in Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02660580Phase 3

  Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · First submitted before Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi

• Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male VolunteersCompletedNCT04238663Phase 1

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi

• A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic ResponseCompletedNCT05051943
• MSB11456 in Participants With Moderately to Severely Active Rheumatoid ArthritisCompletedNCT04512001Phase 3

  Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · First submitted after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi

• Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of AgeTerminatedNCT03563222Phase 4
• Safety and Efficacy of a 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Trauma PatientsCompletedNCT03338218Phase 4
• Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)WithdrawnNCT04807478
• Evaluation of the AMICUS RBCx System in Sickle Cell PatientsCompletedNCT02372877Not applicable

  Sponsor listed in the registry: Fenwal, Inc. · First submitted after Fenwal, Inc. became part of Fresenius Kabi

• Oral Nutritional Supplementation of Hemodialysis PatientsCompletedNCT05333692Not applicable

  Sponsor listed in the registry: Fresenius Kabi Taiwan Ltd.

• Efficacy and Safety Study of a Low-carbohydrate Tube Feed in Critically Ill Patients Under Insulin TherapyTerminatedNCT02503527Not applicable
• Quality of Care of Oncological Patients With HPNTerminatedNCT03425435
• bIosimilar of aDalimumab, an European evAluationStatus unknownNCT05190484
• Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and InfantsTerminatedNCT02579265Phase 3
• Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSVCompletedNCT04540627Phase 1

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi

• Efficacy & Safety of SmofKabiven Emulsion for Infusion vs Hospital Compounded "All in One" for Parenteral NutritionCompletedNCT03792100Phase 3
• Efficacy and Safety of SmofKabiven Peripheral Versus Compounded EmulsionCompletedNCT03792087Phase 3
• A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03296163Phase 3

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi

• A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male VolunteersCompletedNCT04238650Phase 1

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi

• A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male VolunteersCompletedNCT03293654Phase 1

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi

• Three-Chamber Bags Retrospective Study in SpainCompletedNCT03284398
• Reaching Protein Target With SmofKabiven® Extra Nitrogen vs Olimel N9E During the Early Phase of Acute Critical IllnessTerminatedNCT03992716Phase 4
• Observational Cohort Study on the Use of Parenteral Nutrition and Clinical Outcomes in Adult Critically Ill PatientsCompletedNCT04143503
• Comparison of PK and Tolerability of MSB11022 Administered by AI or PFSCompletedNCT04018599Phase 1

  Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · First submitted after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi

• Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456CompletedNCT03282851Phase 1

  Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · Unclear whether first submitted before or after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi

• MSB11022 in Moderate to Severe Rheumatoid ArthritisCompletedNCT03052322Phase 3

  Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · Unclear whether first submitted before or after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi

• Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's LymphomaCompletedNCT02268045Phase 3

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi

• Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of AgeWithdrawnNCT03481894Phase 4
• Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC PatientsCompletedNCT02069704Phase 1

  Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi

• Nutrition Insights Day AsiaCompletedNCT03606603